NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular diseases. Established with a research-oriented approach, it aims to address unmet medical needs through advanced science and targeted treatments. The company is listed on the stock exchange under the ticker NAMS and operates with a focus on improving patient outcomes in the cardiovascular space.
Company News
NewAmsterdam Pharma reported Q2 2025 earnings with $19.1 million in revenue, exceeding consensus estimates. The company showed progress in clinical trials for obicetrapib, a cholesterol-lowering therapy, and maintained strong cash reserves while preparing for potential European market entry.
NewAmsterdam Pharma announced positive results from a pre-specified Alzheimer's disease biomarker analysis in its Phase 3 BROADWAY trial, showing statistically significant reductions in key biomarkers in both the full study population and in ApoE4 carriers. The findings support the potential of obicetrapib, a CETP inhibitor, to prevent Alzheimer'...
NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the grant of inducement share options and restricted stock units to new hires, including the new Chief People Officer. The grants are aimed at incentivizing and retaining key personnel.
NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the closing of a $479.0 million public offering of ordinary shares and pre-funded warrants. The net proceeds will be used to fund the development of the company's lead product, obicetrapib, an oral LDL-lowering therapy.
NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the pricing of a $416.5 million public offering of ordinary shares and pre-funded warrants. The proceeds will be used to advance the development of the company's lead product candidate, obicetrapib, for the treatment of cardiovascular disease.
